STERIS Reports Strong FY26 Results, Issues Positive FY27 Guidance, and Authorizes $1B Share Buyback

summarizeSummary

STERIS plc announced strong fiscal year 2026 financial results, provided an optimistic outlook for fiscal year 2027, and authorized a new $1 billion share repurchase program.

check_boxKey Events

• Strong Fiscal 2026 Financial Performance

  STERIS reported a 9% increase in full-year fiscal 2026 revenue from continuing operations to $5.9 billion, with constant currency organic revenue growth of 7%. Adjusted diluted EPS rose to $10.17 from $9.22 in fiscal 2025, and free cash flow increased to $982.9 million.

• Positive Fiscal 2027 Outlook

  The company anticipates fiscal 2027 revenue to increase 7-8% and constant currency organic revenue growth of 6-7%. Adjusted diluted EPS is projected to be between $11.10 and $11.30, representing a 9-11% increase over fiscal 2026.

• New $1 Billion Share Repurchase Program

  STERIS's Board of Directors authorized a new share buyback program for up to $1 billion of ordinary shares, replacing the previous authorization. This program allows for repurchases through open market transactions, including 10b5-1 plans.

• Strategic Investment in New Manufacturing Plant

  The company plans a strategic investment of approximately $60 million over two years to build a new sterility assurance manufacturing plant in Mentor, Ohio, expected to be operational by late calendar 2027.

auto_awesomeAnalysis

STERIS plc delivered robust financial performance for fiscal year 2026, with significant increases in revenue and adjusted EPS. The company's positive outlook for fiscal year 2027, projecting continued growth in both revenue and adjusted EPS, suggests ongoing operational strength. The authorization of a new $1 billion share repurchase program underscores management's confidence in the company's valuation and commitment to returning capital to shareholders.